Login / Signup

Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database.

Michael V ChioreanChristina HaPeter HurPuza P SharmaDavid GrubenNabeel H Khan
Published in: Digestive diseases and sciences (2023)
In this real-world analysis in a mostly bio-experienced population, the majority of US patients with UC initiating tofacitinib remained on therapy at 12 months, and OCS use was reduced with tofacitinib treatment. HCRU (all patients) and UC-related costs were reduced in bio-experienced patients. The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs.
Keyphrases